Aging Population Fuels Demand in Neurodegenerative Diseases Drugs Market

The global neurodegenerative diseases drugs market is poised for substantial growth over the next decade. Estimated at US$ 58.4 Bn in 2025, it is forecast to reach US$ 85.0 Bn by 2032, expanding at a compound annual growth rate (CAGR) of 5.5% during the 2025–2032 period. Driving this momentum are cutting-edge biologic therapies, biomarker-led diagnostics, and expanding regulatory approvals for early-stage disease treatments.

Aging Population and Early Diagnosis Drive Market Expansion

A significant driver of this market is the global aging population, which is increasing the incidence of Alzheimer’s, Parkinson’s, and multiple sclerosis. Countries with aging demographics are facing a higher disease burden, creating urgency for innovative therapies that can slow disease progression or modify underlying mechanisms.

Early diagnosis has emerged as a powerful growth enabler. With the approval of lecanemab in the U.S., Japan, and parts of Europe for early-stage Alzheimer’s, healthcare systems are upgrading their diagnostic capacities. Investment in PET imaging, CSF biomarker assays, and blood-based diagnostics is growing, expanding the treatment-eligible population.

Promising data from Eli Lilly’s donanemab trial showed a 35% reduction in cognitive decline in early Alzheimer’s patients. These results support the development and reimbursement of therapies for the prodromal or mild cognitive impairment phase, reshaping payer strategies and market access timelines.

Shifting Treatment Paradigms: Immunomodulators and Biologics Lead the Way

A key trend transforming the market is the shift from symptomatic treatments to targeted immunomodulation and biologics. Immunomodulators, in particular, are projected to capture 43.5% of the market share in 2025 due to their success in controlling neuroinflammatory mechanisms, especially in diseases like multiple sclerosis (MS).

The MS segment remains dominant with an estimated 62.6% market share in 2025. The disease’s autoimmune nature makes it highly responsive to immunotherapy, and more than 20 Disease-Modifying Therapies (DMTs) have received global approval. This disease indication continues to attract consistent funding, early adoption, and regulatory momentum.

Meanwhile, dopamine agonists are gaining ground in Parkinson’s management. With improved delivery mechanisms and lower side-effect profiles compared to levodopa, drugs such as pramipexole, ropinirole, and rotigotine are increasingly being used in early stages of the disease to delay motor complications.

Reimbursement Gaps and Limited Diagnostics Remain Key Challenges

Despite promising innovation, challenges persist. The lack of widespread diagnostic adoption limits the rollout of disease-modifying drugs. A 2024 survey by the Alzheimer’s Association revealed that less than 30% of neurologists in the U.S. routinely order amyloid PET or CSF testing—mainly due to cost and accessibility concerns. Without diagnostic confirmation, many novel treatments are underutilized.

Reimbursement systems in many countries still favor low-cost symptomatic therapies, delaying the adoption of newer drugs with higher upfront costs. Clinician skepticism over long-term benefits further adds to the inertia, particularly for therapies requiring advanced imaging and biomarker validation.

Emerging Opportunities in Regenerative Therapies and Stem Cells

An exciting frontier in the market is the integration of stem cell therapies. Unlike conventional treatments that aim to manage symptoms, regenerative approaches promise neuronal restoration and long-term disease modification. Companies are now developing drugs that improve the success rate of stem cell-based treatments through adjunctive immunomodulators and environment-optimizing small molecules.

In 2024, BlueRock Therapeutics, a subsidiary of Bayer, began Phase 2 trials of its iPSC-derived dopamine cell therapy for Parkinson’s. Early results showed motor improvements and strong safety profiles, reinforcing investor interest in combining stem cell research with neuropharmacology.

North America Leads Market Growth with Accelerated Drug Approvals

North America, particularly the United States, is expected to dominate the global market with a projected 51.8% share in 2025. The FDA’s full approval of Eisai and Biogen’s Leqembi for Alzheimer’s was a major breakthrough, marking the first full traditional approval of an anti-amyloid therapy. This triggered a cascade of policy and reimbursement adjustments, including expanded coverage from the Centers for Medicare & Medicaid Services (CMS).

Canada, although more conservative, approved Leqembi in 2023, albeit with tighter reimbursement restrictions. Still, both countries are signaling increased openness toward innovative treatments backed by strong biomarker data and real-world outcomes.

Europe Prioritizes Cost-Effectiveness and Real-World Evidence

Europe presents a more cautious but strategic market. While the European Medicines Agency (EMA) granted conditional approval for Leqembi in late 2024, Germany’s G-BA rated it as having a “minor additional benefit”, impacting national reimbursement schemes. France and other EU countries are taking similar cost-benefit-focused approaches.

To address this, Europe is investing in real-world data infrastructure and decentralized clinical trials. The Innovative Health Initiative (IHI) has directed over €100 million into collaborative neurodegenerative projects like NEUROCURE and EPND, aiming to refine patient stratification and accelerate therapeutic validation.

Asia Pacific Emerges as an Innovation Hub in Neurodegeneration

The Asia Pacific region is quickly gaining momentum, fueled by demographic urgency, government-backed R&D, and progressive regulatory frameworks. Japan, facing the world's highest proportion of elderly citizens, approved lecanemab in 2023 and included it under National Health Insurance—demonstrating agility in public health response.

China is investing heavily under its Healthy China 2030 initiative. Green Valley Pharmaceuticals is spearheading drug development with GV-971, a marine-based Alzheimer’s therapy now in global Phase 3 trials. South Korea is focusing on precision therapies, with companies like Medytox and Peptron advancing peptide and botulinum-based platforms.

Competitive Landscape Remains Fragmented with Rising Biotech Participation

The neurodegenerative drugs market remains fragmented, with major pharmaceutical players leading approvals and emerging biotechs driving disruptive innovations. While firms like Biogen, Pfizer, Roche, and Novartis hold mature pipelines and commercial assets, smaller players are increasingly focused on gene therapies, antisense oligonucleotides, and next-generation biologics.

Strategic collaborations are rising, as large firms seek to bolster pipelines through acquisitions or co-development deals. The entry of platform-based biotech companies is expanding the market’s capability to address rare genetic neurodegenerative diseases like Huntington’s and ALS.

Key Developments Reshaping the Market

In July 2025, Klotho Neurosciences received Orphan Drug Designation from the FDA for KLTO-202, a novel gene therapy for Amyotrophic Lateral Sclerosis (ALS). This provides the company with 7 years of market exclusivity, tax credits, and user fee waivers, creating a favorable commercialization outlook.

In March 2025, Alpha Cognition Inc. officially launched ZUNVEYL, a new treatment for mild to moderate Alzheimer’s disease. The launch reflects the growing commercial potential of accessible and clinically validated cognitive enhancers for the aging population.

Companies Driving Innovation in the Market

Key players in the neurodegenerative diseases drugs market include:

• Biogen

• Pfizer, Inc.

• Hoffmann-La Roche Ltd.

• Merck & Co., Inc.

• Novartis AG

• Sanofi

• Teva Pharmaceutical Industries Ltd.

• Orion Pharma

• UCB S.A.

• ACADIA Pharmaceuticals Inc.

• Lundbeck A/S

• Mitsubishi Tanabe Pharma Corporation

Conclusion

The neurodegenerative diseases drugs market is transitioning from symptom management to mechanism-driven therapies. As early diagnosis becomes more prevalent and precision medicine advances, the industry is gearing up for a new era marked by long-term disease modification, regenerative approaches, and personalized treatment pathways. With regional markets evolving in different trajectories, a global convergence around biomarker validation, regulatory innovation, and payer alignment will be essential to unlock the full potential of this high-impact healthcare segment.